StockData
C4 Therapeutics, Inc. logo

C4 Therapeutics, Inc. (CCCC) balance sheet

CCCCNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/302% below fair value
$2.48+0.04 (+1.64%)

Close on Nov 20, 2026Market cap $305.10MP/E –Yield –

C4 Therapeutics, Inc. balance sheet

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin
–
Operating margin
-319.0%
Net margin
-289.4%
Return on equity, FY2025
-44.4%

Financial strength

Current ratio
5.45
Debt to equity
–
Debt to assets
–
Cash to current liabilities
162.9%

Valuation

P/E ratio
–
Price to sales
8.71
Price to book
1.23
Dividend yield
–

See a number that looks wrong?